Effects of hormone therapy on depressive symptoms and cognitive functions in women with alzheimer disease: A 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone

American Journal of Geriatric Psychiatry

Volumn 18, Issue 1, 2010, Pages 11-20

  Valen Sendstad, Arnhild ^a   Engedal, Knut ^b,c   Stray Pedersen, Babill ^b   Strobel, Carsten ^a   Barnett, Liv ^a   Meyer, Nicolay ^a   Nurminemi, Minna ^d,e  

^a LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e Biometrics   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CYANOCOBALAMIN; ESTRADIOL PLUS NORETHISTERONE ACETATE; PLACEBO;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANXIETY; ARTHRALGIA; ARTICLE; BARTHEL INDEX; BRAIN INFARCTION; BREAST TENDERNESS; CLINICAL TRIAL; COGNITION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DAILY LIFE ACTIVITY; DEEP VEIN THROMBOSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EDUCATIONAL STATUS; FALLING; FEMALE; FRACTURE; GENOTYPE; HORMONAL THERAPY; HUMAN; HYPERTENSION; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEMORY; MOOD; NIPPLE MALFORMATION; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STATISTICAL MODEL; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; WORD RECOGNITION;

EID: 74349086281     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e3181beaaf4     Document Type: Article

References (45)

1. Launer LJ, Andersen K, Dewey ME, et al: Rates and risk factors for dementia and Alzheimer's disease: results from EURODERM pooled analyses. Neurology 1999; 52:78-84
2. Azad NA, Muneraarah AB, Loy-English I: Gender differences in dementia risk factors. Gend Med 2007; 4:120-129
3. McEwen BS, Alves SE, Bulloch K, et al: Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997; 48(5 supp 7):S8-S15
4. Kawas C, Resnick S, Morrison A, et al: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. Neurology 1997; 48:1517-1521
5. Zandi PP, Carlson MC, Plassmann BL, et al: Hormone replacement therapy and incidence of Alzheimer disease on older women: the Cache County Study. JAMA 2002; 288:2123-2129
6. Rapp SR, Espeland MA, Shumaker SA, et al: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory study: a randomized controlled trial. JAMA 2003; 289:2663-2672
7. Shumaker SA, Legault C, Rapp SR, et al: Estrogen plus proges-tin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory study: a randomized controlled trial. JAMA 2003; 289:2651-2662
8. LethabyA, HogervorstE, Richards M, et al: Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. number: CD003122. DOI: 10.1002/14651858.CD003122. pub2 (Pubitemid 351807570)
9. Yaffe K, Haan M, Byers A, et al: Estrogen use, ApoE and cognitive decline: evidence of gene-environment interaction. Neurology 2000; 54:1949-1954
10. O'Hara R, Schroder CM, Bloss C, et al: Hormone replacement therapy and longitudinal cognitive performance in postmenopausal women. Am J Geriatr Psychiatry 2005; 13:1107-1110
11. Ryan J, Scali J, Carriere I, et al: Hormonal treatment, mild cognitive impairment and Alzheimer's disease. Int Psychogeriatr 2008; 20:47-56
12. Asthana S, Baker LD, Craft S, et al: High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57:605-612
13. Mulnard RA, Cotman CW, Kawas C, et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000; 283:1007-1015
14. Henderson VW, Paganini-Hill A, Miller BL, et al: Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54:295-301
15. Bhavnani BR: Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Bio-chem Mol Biol 2003; 85:473-482
16. Gleason CE, Cholerton B, Carlsson CM, et al: Neuroprotective effects of female sex steroids in humans: current controversies and future directions. Cell Mol Life Sci 2005; 62:299-312
17. Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89:484-490
18. Struble RG, Cady C, Nathan BP, et al: Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front Biosci 2008; 13:5387-5405
19. Baker LD, Sambamurti K, Craft S, et al: 17 /3-Estradiol reduces plasma A /340 for HRT-naïve postmenopausal women with Alzheimer disease. Am J Geriatr Psychiatry 2003; 11:239-244
20. Yen YC, Rebok GW, Gallo JJ, et al: ApoE4 allele is associated with late-life depression: a population-based study. Am J Geriatr Psychiatry 2007; 15:858-868
21. Sunderman EE, Gilbert PE, Murphy C: Apolipoprotein E e4 genotype and gender: effects on memory. Am J Geriatr Psychiatry 2007; 15:869-878
22. Corsentino EA, Sawyer K, Sachs-Ericsson N, et al: Depressive symptoms moderate the influence of the apolipoproteine e4 allele on cognitive decline in a sample of community dwelling older adults. Am J Geriatr Psychiatry 2009; 17:155-165
23. West R, Beeri MS, Schmeidler J, et al: Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. Am J Geriatr Psychiatry 2008; 16:781-785
24. Mattis S: Dementia Rating Scale: Professional Manual. Odessa, FL, Psychological Assessment Resources, 1988
25. Morris JC, Heyman A, Mohs RC, et al: The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39:1159-1165
26. Welsh KA, Butters N, Mohs RC, et al: The consortium to establish a registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994; 44: 609-614
27. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-194
28. Salmon DP, Thal LJ, Butters N, et al: Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990; 40:1225-1230
29. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
30. Kaplan EF, Goodglass H, Weintraub S: The Boston Naming Test (2nd edition). Philadelphia, Lea and Febiger, 1983
31. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
32. Wechsler D: WAIS-R Manual. New York, The Psychological Corporation, 1981
33. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery. Theory and Clinical Interpretation. Tuscon, Neuro-psychology Press, 1985
34. Reisberg B, Ferris SH, de Leon MJ, et al: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139:1136-1139
35. Mahoney Fl, Barthel DW: Functional Evaluation: The Barthel Index Rehabilitation. Annual Meeting, Baltimore City Society, April 1965; pp 61-65
36. Annerstedt L, Elmståhl S, Ingvad B, et al: Family caregiving in dementia\-an analysis of the caregiver's burden and the "breaking- point" when home care becomes inadequate. Scand J Public Health 2000; 28:23-31
37. Whooley MA, Grady D, Cauley JA: Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med 2000; 15:535-541
38. Miller KJ, Conney JC, Rasgon NL, et al: Mood symptoms and cognitive performance in women estrogen users and non-users and men. J Am Geriatric Soc 2002; 50:1826-1830
39. Hays J, Ockene JK, Brunner RL, et al: Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348:1839-1854
40. Stern Y, Gurlan B, Tatemichi TK, et al: Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 1994; 271:1004-1010
41. Scarmeas N, Albert SM, Manley JJ, et al: Education and rates of cognitive decline in incident Alzheimer's disease. J Neurol Neu-rosurg Psychiatry 2006; 77:308-316
42. Burkhardt MS, Foster JK, Laws SM, et al: Oestrogen replacement therapy may improve memory functioning in the absence of APOE e4. J Alzheimers Dis 2004; 6:221-228
43. Rippon GA, Tang MX, Lee JH, et al: Familiar Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology 2006; 66:35-40
44. Rossouw JE, Anderson GL, Prentice RL, et al: Risk and benefits of estrogen plus progesterone in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333
45. Turgeon JL, Carr MC, Maki PM, et al: Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006; 27:575-605